| Autor: |
Morales-Núñez JJ; Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico., Muñoz-Valle JF; Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico., Meza-López C; Pediatric Service, Nuevo Hospital Civil de Guadalajara 'Dr. Juan I. Menchaca', University of Guadalajara, Guadalajara 44340, Mexico., Wang LF; Programmed in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore., Machado Sulbarán AC; Institute for Research on Cancer in Childhood and Adolescence, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico., Torres-Hernández PC; Immunology Laboratory, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico., Bedolla-Barajas M; Allergy and Clinical Immunology Service, Nuevo Hospital Civil de Guadalajara 'Dr. Juan I. Menchaca', University of Guadalajara, Guadalajara 44340, Mexico., De la O-Gómez B; University Center for Exact Sciences and Engineering (CUCEI), University of Guadalajara, Guadalajara 44340, Mexico., Balcázar-Félix P; Immunology Laboratory, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico., Hernández-Bello J; Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico. |
| Abstrakt: |
The main expected result of a vaccine against viruses is the ability to produce neutralizing antibodies. Currently, several vaccines against SARS-CoV-2 are being applied to prevent mortal complications, being Pfizer-BioNTech (BNT162b2) one of the first to be authorized in the USA and Mexico (11 December 2020). This study evaluated the efficacy of this vaccine on antibody production with neutralizing capacity and its side effects in healthcare workers with and without prior SARS-CoV-2 infection and in a group of unvaccinated individuals with prior COVID-19. The main findings are the production of 100% neutralizing antibodies in both groups after the second dose, well-tolerated adverse effects, the possible presence of immunosenescence, and finally, we support that a single dose of this vaccine in individuals with prior COVID-19 would be sufficient to achieve an immunization comparable to people without prior COVID-19 with a complete vaccination program (2 doses). |
